MA56341B1 - Combinaison d'ibuprofène et de tramadol pour soulager la douleur - Google Patents
Combinaison d'ibuprofène et de tramadol pour soulager la douleurInfo
- Publication number
- MA56341B1 MA56341B1 MA56341A MA56341A MA56341B1 MA 56341 B1 MA56341 B1 MA 56341B1 MA 56341 A MA56341 A MA 56341A MA 56341 A MA56341 A MA 56341A MA 56341 B1 MA56341 B1 MA 56341B1
- Authority
- MA
- Morocco
- Prior art keywords
- tramadol
- combination
- ibuprofen
- pain relief
- dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382583 | 2019-07-09 | ||
| PCT/EP2020/069306 WO2021005129A1 (en) | 2019-07-09 | 2020-07-08 | Combination of ibuprofen and tramadol for relieving pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56341B1 true MA56341B1 (fr) | 2023-07-31 |
Family
ID=67480112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56341A MA56341B1 (fr) | 2019-07-09 | 2020-07-08 | Combinaison d'ibuprofène et de tramadol pour soulager la douleur |
Country Status (21)
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB971700A (en) | 1961-02-02 | 1964-09-30 | Boots Pure Drug Co Ltd | Anti-Inflammatory Agents |
| US3652589A (en) | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
| GB1497044A (en) | 1974-03-07 | 1978-01-05 | Prodotti Antibiotici Spa | Salts of phenyl-alkanoic acids |
| AU661723B2 (en) | 1991-10-30 | 1995-08-03 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
| US5516803A (en) * | 1991-10-30 | 1996-05-14 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
| IT1264855B1 (it) | 1993-06-21 | 1996-10-17 | Zambon Spa | Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici |
| IT1264857B1 (it) | 1993-06-21 | 1996-10-17 | Zambon Spa | Composizione farmaceutica liquida per uso orale contenente acido 2-(4-isobutilfenil) propionico |
| US6348216B1 (en) | 1996-06-10 | 2002-02-19 | Knoll Pharmaceutical Company | Ibuprofen and narcotic analgesic compositions |
| WO2000025769A1 (en) | 1998-11-02 | 2000-05-11 | Ortho-Mcneil Pharmaceutical, Inc. | Analgesic regimen |
| US6251945B1 (en) | 1999-01-14 | 2001-06-26 | Knoll Aktiengesellschaft | Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| US6211246B1 (en) | 1999-06-10 | 2001-04-03 | Mcneil-Ppc, Inc. | Rapidly absorbed liquid compositions |
| US6342530B1 (en) | 2000-11-14 | 2002-01-29 | Farmacon-Il, Llc | Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt |
| US6727286B2 (en) | 2001-11-02 | 2004-04-27 | Cumberland Pharmaceuticals Inc. | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
| JP5185488B2 (ja) | 2001-11-02 | 2013-04-17 | カンバーランド ファーマシューティカルズ,インコーポレーテッド | 2−(4−イソブチルフェニル)プロピオン酸の医薬組成物 |
| EP1558234B1 (en) | 2002-10-25 | 2007-05-23 | Dompé S.P.A. | Painless injectable compositions containing salt of 2-arylpropionic acids |
| US20070117826A1 (en) * | 2005-11-23 | 2007-05-24 | Forest Laboratories, Inc. | Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone |
| EP2149546A1 (en) * | 2008-07-31 | 2010-02-03 | Laboratorios Del. Dr. Esteve, S.A. | Salts of tramadol and ibuprofen and their crystal form in the treatment of pain |
| EP2381937A2 (en) | 2008-12-31 | 2011-11-02 | Upsher-Smith Laboratories, Inc. | Opioid-containing oral pharmaceutical compositions and methods |
| AU2010224063B2 (en) | 2009-03-12 | 2015-04-16 | Cumberland Pharmaceuticals Inc | Administration of intravenous ibuprofen |
| US8871810B2 (en) | 2009-07-15 | 2014-10-28 | Cumberland Pharmaceuticals Inc. | Treating critically ill patients with intravenous ibuprofen |
| US8735452B2 (en) | 2009-07-15 | 2014-05-27 | Cumberland Pharmaceuticals Inc. | Treating patients with intravenous ibuprofen |
| ES2356762B1 (es) * | 2009-09-04 | 2011-11-24 | Farmalider S.A. | Composicion farmaceutica de ibuprofeno, tramadol y un aminoacido basico, procedimiento para su preparacion y utilizacion de la misma. |
| MX2010004974A (es) | 2010-05-04 | 2011-11-23 | Senosiain S A De C V Lab | Combinacion de un aine y un aminoacido. |
| US8895622B2 (en) | 2011-04-12 | 2014-11-25 | Revogenex Ireland Ltd. | Intravenous administration of tramadol |
| PT2636406E (pt) | 2012-02-20 | 2015-11-20 | Pharmaceutical Solutions Industry Ltd | Perfusão intravenosa de ibuprofeno |
| ES2423866B1 (es) * | 2012-02-22 | 2014-06-10 | Farmalider, S.A. | Composición farmaceútica de ibuprofeno y tramadol para inyección |
| ES2540151B1 (es) * | 2013-10-11 | 2016-02-29 | Farmalider S.A. | Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico |
| CN106413717A (zh) * | 2014-04-10 | 2017-02-15 | 查尔斯顿实验室公司 | 药物组合物 |
-
2020
- 2020-07-08 SI SI202030232T patent/SI3996699T1/sl unknown
- 2020-07-08 US US17/624,601 patent/US12514833B2/en active Active
- 2020-07-08 CN CN202080049962.XA patent/CN114080221B/zh active Active
- 2020-07-08 WO PCT/EP2020/069306 patent/WO2021005129A1/en not_active Ceased
- 2020-07-08 MD MDE20220551T patent/MD3996699T2/ro unknown
- 2020-07-08 MA MA56341A patent/MA56341B1/fr unknown
- 2020-07-08 PT PT207402660T patent/PT3996699T/pt unknown
- 2020-07-08 AU AU2020309160A patent/AU2020309160B2/en active Active
- 2020-07-08 RS RS20230732A patent/RS64500B1/sr unknown
- 2020-07-08 HU HUE20740266A patent/HUE062529T2/hu unknown
- 2020-07-08 EP EP20740266.0A patent/EP3996699B1/en active Active
- 2020-07-08 MX MX2022000373A patent/MX2022000373A/es unknown
- 2020-07-08 JP JP2022501259A patent/JP7656339B2/ja active Active
- 2020-07-08 BR BR112022000242A patent/BR112022000242A2/pt unknown
- 2020-07-08 PL PL20740266.0T patent/PL3996699T3/pl unknown
- 2020-07-08 MY MYPI2021007550A patent/MY207573A/en unknown
- 2020-07-08 DK DK20740266.0T patent/DK3996699T3/da active
- 2020-07-08 CA CA3145632A patent/CA3145632C/en active Active
- 2020-07-08 ES ES20740266T patent/ES2952013T3/es active Active
- 2020-07-08 HR HRP20230677TT patent/HRP20230677T1/hr unknown
- 2020-07-08 FI FIEP20740266.0T patent/FI3996699T3/fi active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE062529T2 (hu) | 2023-11-28 |
| US12514833B2 (en) | 2026-01-06 |
| AU2020309160B2 (en) | 2025-06-26 |
| CA3145632C (en) | 2024-03-12 |
| MY207573A (en) | 2025-03-05 |
| BR112022000242A2 (pt) | 2022-05-31 |
| JP2022540854A (ja) | 2022-09-20 |
| JP7656339B2 (ja) | 2025-04-03 |
| HRP20230677T1 (hr) | 2023-10-13 |
| ES2952013T3 (es) | 2023-10-26 |
| MX2022000373A (es) | 2022-02-10 |
| FI3996699T3 (fi) | 2023-08-01 |
| RS64500B1 (sr) | 2023-09-29 |
| EP3996699B1 (en) | 2023-06-28 |
| AU2020309160A1 (en) | 2022-02-17 |
| PT3996699T (pt) | 2023-07-27 |
| MD3996699T2 (ro) | 2023-11-30 |
| DK3996699T3 (da) | 2023-07-24 |
| CA3145632A1 (en) | 2021-01-14 |
| US20220249414A1 (en) | 2022-08-11 |
| CN114080221A (zh) | 2022-02-22 |
| WO2021005129A1 (en) | 2021-01-14 |
| SI3996699T1 (sl) | 2023-10-30 |
| CN114080221B (zh) | 2023-12-05 |
| PL3996699T3 (pl) | 2023-10-30 |
| EP3996699A1 (en) | 2022-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29273B1 (fr) | Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur | |
| MA48051B1 (fr) | Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide | |
| MA69295B1 (fr) | Dose de départ de conjugués de pth | |
| MA29871B1 (fr) | Composition pharmaceutique concue pour ameliorer la fonction cognitive | |
| MA31205B1 (fr) | Combinaisons d'agents therapeutiques pour le traitement du cancer | |
| MA37850A1 (fr) | Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale | |
| EA200401009A1 (ru) | Предварительно желатинированный крахмал в композиции с контролируемым высвобождением | |
| EA200200106A1 (ru) | Фармацевтическая композиция леводопа/карбидопа/энтакапон | |
| MA34158B1 (fr) | Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée | |
| MA34553B1 (fr) | Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué | |
| MA52861B1 (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple | |
| MA53927B1 (fr) | Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel | |
| MA52154B1 (fr) | Composition pharmaceutique pour l'anémie | |
| MX388825B (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| WO2002011694A3 (en) | Compositions and dosage forms for application in the oral cavity in the treatment of mykoses | |
| JP2023549849A5 (cg-RX-API-DMAC7.html) | ||
| MA49396A (fr) | Traitement de la migraine avec acétyl-leucine | |
| MA45202B1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
| BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
| MA46778A1 (fr) | Composition intranasale comprenant de la bétahistine | |
| MA51675B1 (fr) | Compositions pharmaceutiques pour le traitement de la douleur postopératoire | |
| MA54276B1 (fr) | Montélukast destinée au traitement de l'arthrose de la main | |
| MA54028B2 (fr) | Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène | |
| MA27731A1 (fr) | Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete | |
| FR3097744B1 (fr) | Produit de combinaison pour aider au maintien des défenses naturelles de l’organisme |